Pharmacogenomics & Personalized Medicine

Papers
(The H4-Index of Pharmacogenomics & Personalized Medicine is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Angiotensin System Polymorphisms’ in SARS-CoV-2 Positive Patients: Assessment Between Symptomatic and Asymptomatic Patients: A Pilot Study26
Cuproptosis-Related Gene – SLC31A1, FDX1 and ATP7B – Polymorphisms are Associated with Risk of Lung Cancer15
<p>Development of Customizable Implementation Guides to Support Clinical Adoption of Pharmacogenomics: Experiences of the Implementing GeNomics In pracTicE (IGNITE) Network</p>10
<p>Clinical Utility of CYP2C19 Genotype-Guided Antiplatelet Therapy in Patients at Risk of Adverse Cardiovascular and Cerebrovascular Events: A Review of Emerging Evidence</p>10
Variation of Genomic Sites Associated with Severe Covid-19 Across Populations: Global and National Patterns10
<p>Carvedilol Alters Circulating MiR-1 and MiR-214 in Heart Failure</p>9
Pharmacogenomics and Personalized Medicine in Type 2 Diabetes Mellitus: Potential Implications for Clinical Practice9
Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer8
<p>Implementation of Pharmacogenetics to Individualize Treatment Regimens for Children with Acute Lymphoblastic Leukemia</p>8
0.039758920669556